CDK9 and B-cell chronic lymphocytic leukemia: We showed that the IC50 values of various CDK9 inhibitors against CLL samples correlated with the IC50 against CDK9, but not against other CDKs, further supporting that CDK9 inhibition is a common mechanism of action for these compounds.